To date, several preclinical PET studies have been conducted using antibodies, peptides, and small molecules to quantify PD-L1 expression in tumours during immunotherapy.9,316–318 Josefsson et al. labelled anti–PD-L1 antibodies with indium-111 for SPECT/CT imaging and in vivo biodistribution studies. Here, CD274 is linked to neoplasm.